Trial Outcomes & Findings for Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction. (NCT NCT02836899)
NCT ID: NCT02836899
Last Updated: 2026-03-10
Results Overview
Acute kidney injury (AKI) is defined by KDIGO criteria as an abrupt (within 48h) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 μmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or, finally, a reduction in urine output with a documented oliguria of \< 0.5 ml/Kg/h for \>6h.
COMPLETED
PHASE3
250 participants
7 days
2026-03-10
Participant Flow
Participant milestones
| Measure |
Control
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
Placebo: This is the placebo group. Nitrogen will be added instead of nitric oxide.
|
Nitric Oxide
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Nitric Oxide: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
|
|---|---|---|
|
Overall Study
STARTED
|
125
|
125
|
|
Overall Study
COMPLETED
|
125
|
125
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.
Baseline characteristics by cohort
| Measure |
Control
n=125 Participants
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
Placebo: This is the placebo group. Nitrogen will be added instead of nitric oxide.
|
Nitric Oxide
n=125 Participants
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Nitric Oxide: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
|
Total
n=250 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Region of Enrollment
United States
|
125 participants
n=68 Participants
|
125 participants
n=69 Participants
|
250 participants
n=137 Participants
|
|
BMI
|
28.3 kg/m^2
n=68 Participants
|
28.9 kg/m^2
n=69 Participants
|
28.6 kg/m^2
n=137 Participants
|
|
Age, Continuous
|
66 years
n=68 Participants
|
66 years
n=69 Participants
|
66 years
n=137 Participants
|
|
Sex: Female, Male
Female
|
30 Participants
n=68 Participants
|
26 Participants
n=69 Participants
|
56 Participants
n=137 Participants
|
|
Sex: Female, Male
Male
|
95 Participants
n=68 Participants
|
99 Participants
n=69 Participants
|
194 Participants
n=137 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=68 Participants
|
3 Participants
n=69 Participants
|
5 Participants
n=137 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=68 Participants
|
2 Participants
n=69 Participants
|
4 Participants
n=137 Participants
|
|
Race (NIH/OMB)
White
|
121 Participants
n=68 Participants
|
120 Participants
n=69 Participants
|
241 Participants
n=137 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=68 Participants
|
0 Participants
n=69 Participants
|
0 Participants
n=137 Participants
|
|
ASA Grade
2
|
3 Participants
n=68 Participants
|
7 Participants
n=69 Participants
|
10 Participants
n=137 Participants
|
|
ASA Grade
3
|
94 Participants
n=68 Participants
|
94 Participants
n=69 Participants
|
188 Participants
n=137 Participants
|
|
ASA Grade
4
|
28 Participants
n=68 Participants
|
24 Participants
n=69 Participants
|
52 Participants
n=137 Participants
|
|
NYHA Classification Score
I
|
45 Participants
n=68 Participants
|
38 Participants
n=69 Participants
|
83 Participants
n=137 Participants
|
|
NYHA Classification Score
II
|
64 Participants
n=68 Participants
|
60 Participants
n=69 Participants
|
124 Participants
n=137 Participants
|
|
NYHA Classification Score
III-IV
|
16 Participants
n=68 Participants
|
27 Participants
n=69 Participants
|
43 Participants
n=137 Participants
|
PRIMARY outcome
Timeframe: 7 daysAcute kidney injury (AKI) is defined by KDIGO criteria as an abrupt (within 48h) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.4 μmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or, finally, a reduction in urine output with a documented oliguria of \< 0.5 ml/Kg/h for \>6h.
Outcome measures
| Measure |
Placebo Comparator: Control
n=125 Participants
Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
|
Experimental: Nitric Oxide
n=125 Participants
Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
|
|---|---|---|
|
Number of Participants With Acute Kidney Injury
|
54 Participants
|
55 Participants
|
SECONDARY outcome
Timeframe: 7 days after cardiac surgeryDifference in AKI severity between the two groups using following KDIGO stages.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 1 yearTo study the incidence of acute renal failure requiring RRT
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 6 weeks after cardiac surgeryDifference between groups of MAKE at 6 weeks after surgery. MAKE is a composite outcome of death, new dialysis and worsened renal function (defined as a 25% or greater decline in eGFR compared to the baseline).
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 7 daysAssessment of organ dysfunction through the evaluation of SOFA score
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 48 hours after cardiac surgeryDifference between groups of prolonged cardiovascular support defined as need for vasopressors, inotropic agents, balloon pump, or ventricular-assist device for more than 48 hours after cardiac surgery.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 7 days after cardiac surgeryDifference between groups of maximum daily VIS and duration of vasopressors and or inotropic agents support. VIS is calculated as Dopamine dose (mcg/kg/min) + Dobutamine dose (mcg/kg/min) + 100 x Epinephrine dose (mcg/kg/min) + 10 x Milrinone dose (mcg/kg/min) + 10,000 x Vasopressin dose (units/kg/min) + 100 x Norepinephrine dose (mcg/kg/min) + 10 x Phenilephrine dose (mcg/kg/min).
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 6 weeksDifference of duration of mechanical ventilation
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 6 weeksDifference between groups of ICU-LOS defined as number of days spent in an ICU bed.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 1 yearDifference between groups of hospital LOS defined as number of days spent in a hospital bed.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 6 weeksRenal biomarkers to evaluate renal tubular injury.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 7 daysIncidence and severity of AKI related to presence of CKD at baseline, duration of CPB, duration of aortic cross clamp, levels of free Hb, levels of NO consumption, pulmonary pressure at baseline, cardiovascular risks associated with endothelial dysfunction, scheduled procedure and EuroSCORE II.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 7 days after cardiac surgeryDifference between groups of Incidence of Delirium will be assessed daily in the first 7 days after surgery by using the confusion assessment method for intensive care unit (CAM-ICU).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: One year follow upAnalysis of the quality of life up to 1 year after surgery by the Activity of Daily Living evaluation (by Katz Index) and PROMIS global health.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: up to 1 yearEvaluation of the overall intrahospital mortality and at 28 6 weeks 90 days and 1 year after surgery
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: During and 48 hours after cardiac surgeryBlood methemoglobin levels will be measured to evaluate the oxidation of oxyhemoglobin in the two groups until 48h after surgery.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 weeksDifference between groups of incidence of non fatal stroke will be assessed by at 6 weeks after cardiac surgery.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 72 hours and 1 year follow upIncidence of Perioperative and non-perioperative nonfatal myocardial infarction as defined by the third universal definition of MI released in 2012 by the ESC/ACCF/AHA/WHF.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 24 after surgeryIncidence of postoperative bleeding calculated as the sum of blood loss through thoracic drains from the moment of closure of the chest over a period of 24 hours.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 7 days surgeryDifferences between the two groups of transfusions with plasma and stored or autologous red blood cells (RBCs) recovered using intraoperative cell salvage devices.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 weeksPost-operative infections (e.g., pneumonia, wound infection, endocarditis, central line infection, urinary tract infection, sepsis).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 6 weeksCardiac arrhythmias and other non-cardiac post-operative complications (e.g., hepatobiliary disorders, pneumothorax, pleural effusion, vascular disorders).
Outcome measures
Outcome data not reported
Adverse Events
Control
Nitric Oxide
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place